请仔细阅读说明书并在医师指导下使用

Dabigatran Etexilate Capsules
Dabijiaqunzhi Jiaonang

β- , N-[[2-[[[4-[[[( )]]]]]]]-1- -1H- -5-]]-N-2- -,
.

$C_{34}H_{41}N_7O_5 \cdot CH_4O_3S$
723.86
627.75

NVAF SEE
- .
- <40%
- NYHA ≥ 2
- ≥ 75
- ≥ 65

DVT / PE
DVT / PE

1 110mg 2 150mg

/

NVAF SEE SPAF
300mg 1 150mg
DVT / PE
300mg 1 150mg 5
DVT / PE
300mg 1 150mg
DVT / PE DVT / PE

3 DVT PE
SPAF DVT/PE
220mg 110mg
- 80
-
300mg 220mg
- 75–80
-
-
-
DVT/PE 220mg 110mg

SPAF DVT/PE
75–80 300mg 150mg
220mg 110mg
80 220mg 110mg
>75 CrCL
CrCL<30mL/min

SPAF DVT/PE

220mg 110mg
220mg
110mg
SPAF DVT/PE
CrCL<30mL/min
CrCL<30mL/min

CrCL50– ≤ 80mL/min CrCL30–50mL/min
300mg 150mg 220
mg 110mg
SPAF DVT/PE
<50kg
SPAF DVT/PE

12
2
K
K INR < 2.0
K
K VKA
- CrCL ≥ 50mL/min 3 VKA
- 30mL/min ≤ CrCL 50mL/min 2 VKA

其他
:
150mg
: 6 6
/
-
-
-

64,000 35,000
SEE 12,042 6,059 150mg
5,983 110mg
/ RE-COVER,RE-COVER II 2,553
150mg
/ RE-MEDY,RE-SONATE 2,114 552
RE-COVER / RE-MEDY
150mg
22% SEE 3 14% /
6 15% / 36
16.6% SEE 14.4%
/ / RE-MEDY
RE-SONATE 19.4% 10.5%

1 SEE DVT / PE DVT/PE
SOC ≥ 1/10 ≥
1/100,<1/10 ≥ 1/1,000,<1/100 ≥ 1/10,000,<1/1,000 <1/10,000
1 SEE DVT / PE DVT/PE

z